Biomarker testing is critical for ensuring that cancer patients get the right therapy at the right time. But what happens when new therapies emerge, and their associated biomarkers are not routinely tested for as standard of care?
As the leading oncology diagnostic lab in the US, testing nearly 500,000 cancer patients annually, NeoGenomics is a premier partner for enabling diagnostic market development through its direct-to-provider channels. By harnessing the power of its real-world lab data, NeoGenomics partners with numerous pharmaceutical companies to develop step-by-step precision oncology launch programs designed to drive biomarker awareness.
Learn more about the five tactics that can support your next commercial launch in this NeoEngage case study.
- Have a question or project in mind? Contact us to book a consultation with a data strategist.
- Learn how our NeoEngage™ real-world lab data solutions can accelerate your precision oncology launches.
- Subscribe to our eNews to receive the latest Informatics resources.
- Discover our full product portfolio